Home > Result Summaries: Compounds > rosiglitazone/metformin Result Summaries: rosiglitazone/metformin GSKStudy ID Phase Title Summary (Download) 100344 Phase 3 A 28-Week, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Formulation X in Subjects with Type 2 Diabetes Mellitus (0 citation(s)) 100420 Phase 3 A 24-week open study to investigate the effectiveness, tolerability and efficacy to reach HbA1c-goals of a new oral antidiabetic drug (Avandamet) in patients with type 2 diabetes with inadequate glycemic control under metformin monotherapy (0 citation(s)) 101765 Phase 4 Comparison of the action of the rosiglitazone-metformin fixed-dose combination and of a metformin-sulfonylurea free combination on the b-cell function in type 2 diabetic patients not controlled with metformin alone. (0 citation(s)) 103205 Phase 1 A Bioequivalence Study With a Combination Tablet Formulation of Rosiglitazone and Metformin (2 mg/500 mg) Compared to Concomitant Dosing of Rosiglitazone 2 mg and Metformin 500 mg Commercial Tablets in Chinese Healthy Male Subjects. (0 citation(s)) 104644 phase 4 Mandatory study for Rosiglitazone (0 citation(s)) 104988 Phase 4 Comparison of the effects of rosiglitazone and glimepiride, both given in combination with metformin, on 24-hour glycemia in type 2 diabetes patients not controlled with metformin alone. A 3-month multicentre, randomized, parallel-group, open-label study. (0 citation(s)) 105684 and 105685 Phase 4 "GREAT (German Recent Evaluation of Avandamet Treatment)-Post Marketing Surveillance (PMS) (0 citation(s)) 105709 n\a An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and/or efficacy of Avandamet® administered in Korean Diabetic patients according to the prescribing information (0 citation(s)) 111291 N/A Epidemiologische Nachuntersuchung von Patienten der Studie Avandamet 712753 / 100420 (Ziel-Studie) (0 citation(s)) 113030 phase 4 Evaluation of the duration of oral combination therapy in Type 2 diabetes, prior to the initiation of insulin in the UK (0 citation(s)) 113489_1 N/A An assessment of the Independent effect of oral antidiabetic agents and insulin exposure on the risk of myocardial infarction in type 2 diabetic patients (1 citation(s)) 113492_1 N/A Balanced cohort study of thiazolidinediones (TZDs) and other antidiabetic therapies and coronary heart disease events (1 citation(s)) 113493_1 N/A The risk of cancer associated with TZD's and fibrates: A retrospective cohort study (2 citation(s)) 113497_1 n\a Reports of neoplasms in rosiglitazone clinical trials (1 citation(s)) 113499_1 N/A Cohort study of Thiazolidinediones (TZDs) and other antidiabetic therapies and coronary heart disease outcomes (1 citation(s)) 114040 phase 1 Assessment of relative bioavailability of Avandamet 4 mg + 1000 mg (GSK) in the form of film coated tablets versus Avandamet 2 mg + 500 mg (GSK) in the form of film coated tablets, in healthy volunteers after feeding standardized, using Liquid Chromatography. (0 citation(s)) 712753/001 Phase 1 A Bioequivalence Study with a Combination Tablet Formulation of Rosiglitazone and Metformin (4 mg/1000 mg) Compared to the Commercial Tablet Formulation of AVANDAMET* (2 mg rosiglitazone/500 mg metformin) and a Dose Proportionality Study Comparing the Combination Tablet Formulations of Rosiglita ... (0 citation(s)) 712753/002 Phase 3 A phase III, 24 week, multi-centre, randomised, double-blind, parallel group, dose escalation study of Avandamet (rosiglitazone/metformin) and high dose metformin monotherapy in subjects with poorly controlled type 2 diabetes mellitus (1 citation(s)) 712753/003 Phase 3 A Phase III Multi-Centre, Double-Blind, Randomised, Parallel-Group, Dose Escalation Study Comparing the Effects of 32 Weeks Administration of Avandamet and Metformin on Hba1c Targets in Subjects With Mild Type 2 Diabetes Mellitus (1 citation(s)) 712753/004 phase 3 An open-label trial to evaluate the safety and efficacy of fixed dose rosiglitazone/metformin combination therapy in poorly-controlled subjects with type 2 diabetes mellitus (0 citation(s)) 712753/007 phase 3 A randomized, double-blind trial to evaluate the efficacy and safety of fixed dose rosiglitazone/metformin combination therapy compared to both rosiglitazone and metformin monotherapies in drug naive type 2 diabetes mellitus subjects (1 citation(s)) 712753/008 phase 4 AVANDAMET Compared to Metformin Evaluation Trial (ACME): A 48-week Randomized, Open-label, multicenter study to compare the efficacy and tolerability of AVANDAMET to metformin monotherapy in subjects with Type 2 Diabetes Mellitus who are not achieving glycemic control on submaximal metformin. (0 citation(s)) 712753/009 phase 3 A 24 week, randomised, double blind, parallel study to compare the change in HbA1c with AVANDAMET* (8.0 mg / 2.0 g) plus insulin to placebo plus insulin, in subjects with type 2 diabetes starting insulin therapy (1 citation(s)) 712753/011 Phase 1 A study to assess the effect of food and time of dosing on the pharmacokinetics of Avandamet™ (rosiglitazone maleate 8 mg/metformin HCl 1000 mg administered as 2 ' 4/500) Glucophage XR 1000 mg (given as metformin HCl 2 ' 500 mg) and Avandia™ (rosiglitazone maleate 8 mg) in healthy adult subjects. (0 citation(s)) 712753/012 Phase 1 A study to estimate the pharmacokinetics of six extended release formulations of AVANDAMET (rosiglitazone maleate 4 mg / metformin HCl 1000 mg), compared to the commercial formulation of AVANDAMET (rosiglitazone maleate 2 mg / metformin HCl 500 mg, q12h), and concomitant… (0 citation(s)) 712753/014 Phase 1 A study to assess the steady state pharmacokinetics of repeat oral doses of AVANDAMET XR (combination formulation of rosiglitazone 8mg/metformin 1000mg) and AVANDAMET IR (rosiglitazone 4mg/metformin 500mg) in healthy subjects (0 citation(s)) AVM100264 Phase 3 A randomised, multi-centre, phase IV, double-blind, parallel group study comparing the effects of 52 weeks administration of AVANDAMET and metformin plus sulphonylurea on change in HbA1c from baseline in overweight type 2 diabetics poorly controlled on metformin. (1 citation(s)) AVT105913 phase 4 A randomized, parallel group, double-blind, multi-center study comparing the efficacy and safety of AVANDAMET and metformin after 80 weeks of treatment. (2 citation(s))
